A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening  by Stewart, Hazel et al.
A
t
s
H
S
a
b
A
R
R
A
A
K
H
T
I
D
A
1
m
m
c
p
h
w
t
b
u
t
i
c
o
i
a
h
0Journal of Virological Methods 218 (2015) 59–65
Contents lists available at ScienceDirect
Journal  of  Virological  Methods
j o ur na l ho me  pa ge: www.elsev ier .com/ locate / jv i romet
 novel  method  for  the  measurement  of  hepatitis  C  virus  infectious
itres  using  the  IncuCyte  ZOOM  and  its  application  to  antiviral
creening
azel  Stewarta, Christopher  Bartletta, Douglas  Ross-Thrieplanda,  Joseph  Shawb,
tephen  Grifﬁnb,  Mark  Harrisa,∗
School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom
Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health, St James’s University Hospital, University of Leeds, Leeds LS9 7TF, United Kingdom
rticle history:
eceived 1 December 2014
eceived in revised form 11 March 2015
ccepted 12 March 2015
vailable online 20 March 2015
s  u  m  m  a  r  y
Hepatitis  C  virus  (HCV)  is  a  signiﬁcant  human  pathogen  infecting  3% of the  world  population.  An infec-
tious  molecular  clone  capable  of  replicating  and releasing  infectious  virions  in  cell culture  has  only  been
available  since  2005,  leaving  a signiﬁcant  knowledge  gap  concerning  post-RNA  replication  events  such
as  particle  assembly,  trafﬁcking  and release.  Thus,  a fast,  efﬁcient  and  accurate  method  of  measuring
infectious  viral  titres  is  highly  desirable.  Current  methods  rely  upon  manual  counting  of infected  cell focieywords:
epatitis C virus
itration
ncuCyte ZOOM
iagnosis
ntivirals
and  so  are both  labour-intensive  and  susceptible  to human  error.  Here,  we  report  a novel  protocol,  which
utilises the  IncuCyte  ZOOM  instrument  and related  software  to  accurately  count  infected  cells  and  extrap-
olation  of this  data  to produce  an  infectious  titre, reported  as  infectious  units  per millilitre  (IU/mL).  This
method  reduces  cost,  time  and  error  in experiments.  We  also  demonstrate  that  this  approach  is  amenable
to  high-throughput  compound  screening,  thereby  expediting  the  identiﬁcation  of novel antivirals.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Hepatitis C virus (HCV) is estimated to infect approximately 170
illion people worldwide (Mohd Hanaﬁah et al., 2013) and is the
ajor causative agent of non-alcoholic liver disease, hepatocellular
arcinoma and liver transplants in the developed world. Although
otent direct-acting antivirals have recently become available, the
igh cost of treatment and an unpredictable level of viral resistance,
hich may  emerge following therapy on a wide scale, indicate that
his virus will continue to exert a signiﬁcant health and economic
urden for the foreseeable future. Additionally, basic research
pon HCV remains a priority as the primary focus gradually shifts
owards vaccine development.
Until 2005, HCV research was signiﬁcantly hampered by an
nability to recapitulate the full infectious cycle of the virus in
ell culture systems. However, identiﬁcation and characterisation
f the genotype 2a JFH-1 strain, which both efﬁciently replicates
ts genome and releases infectious viral particles, greatly acceler-
ted laboratory research and subsequently allowed study of the
∗ Corresponding author. Tel.: +44 0113 343 5632.
E-mail address: M.Harris@leeds.ac.uk (M.  Harris).
ttp://dx.doi.org/10.1016/j.jviromet.2015.03.009
166-0934/© 2015 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
entire viral life cycle (Wakita et al., 2005). Since this initial report,
molecular clones based upon genotype 1a and 2b isolates have been
produced (Li et al., 2012, 2014b; Ramirez et al., 2014; Yi et al., 2006),
as well as numerous intergenotypic chimaeric JFH-1 viral genomes
(Gottwein et al., 2009; Li et al., 2014a; Steinmann et al., 2013); all
of which are infectious in cell culture models.
Cell culture-derived HCV titres are generally measured in either
focus-forming units per millilitre (FFU/mL) (reviewed in (Yi, 2010))
or through calculation of the 50% tissue culture infective dose
(TCID50) (Reed and Muench, 1938). Unlike many viruses, HCV
infection does not result in plaque formation, therefore infected
cells are detected by indirect immunoﬂuorescence using antibodies
speciﬁc for virally-encoded proteins (for example, NS5A). For the
majority of infectious HCV isolates developed to date, viral titres
produced from the commonly used Huh-7 hepatoma cells rarely
exceed 105 FFU/mL. However there are extreme cases: titres of only
103 FFU/mL are commonly achieved with the full-length genotype
one clones, whereas the genotype 2a/2a chimaeric JC-1 virus often
produces 106 FFU/mL (Pietschmann et al., 2006) and is therefore
an attractive alternative to the prototypic JFH-1 strain (reviewed in
Vieyres and Pietschmann (2013)).
Although the measurement of viral titre in FFU remains an estab-
lished method within RNA virology (Condit, 2007), in many cases
advancements in technology have resulted in either automated
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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rocesses or the use of surrogate markers, thereby increasing the
ccuracy and through put rate of the assay (for example, the vir-
ual TCID50 method for HIV-1, which measures virion-associated
everse transcriptase activity (Gao et al., 2009; Marozsan et al.,
004); and the competitive virus assay for titration of bovine viral
iarrhoea virus isolates (Muhsen et al., 2013)). To our knowledge,
pproaches such as these have not been adopted for HCV; the
urrently used protocol therefore remains labour-intensive, low-
hroughput and susceptible to signiﬁcant human error during data
nterpretation.
In this manuscript, we describe a novel method of measuring
CV titres in infectious units (IU/mL). The experimental protocol
s an adaptation of the previously-described immunoﬂuorescence-
ased approaches (Lindenbach, 2009; Vieyres and Pietschmann,
013; Yi, 2010), whilst data analysis is a wholly novel technique
tilising the IncuCyte ZOOM (Essen BioScience). The IncuCyte
OOM instrument has been utilised previously in RNA virology
or detection of ﬂuorescent reporter genes during live-cell imaging
Forrest et al., 2014; Tulloch et al., 2014), however to our knowl-
dge this is the ﬁrst application of this instrument to quantiﬁcation
f HCV. This method allows the accurate and precise measure-
ent of HCV titres in a relatively high-throughput setting, thereby
ecreasing labour, reagent cost and human bias. The wide linear
ange of detection exhibited by this method also makes it highly
menable to future high-throughput screens of potential antiviral
ompounds.
. Materials and methods
.1. In vitro transcription of viral RNA
The DNA construct encoding the JFH-1 viral genome (pJFH-
) and a replication-defective control mutant of this plasmid
termed pJFH-1-GND, possessing a GDD > GND mutation within the
NA-dependent-RNA-polymerase active site) has been described
reviously (Wakita et al., 2005). The DNA construct encoding the
himaeric JC-1 virus (pJ6-JFH-1c3) has been described previously
Pietschmann et al., 2006).
DNA constructs were linearised using XbaI, brieﬂy treated with
ungbean nuclease to degrade 3′ overhangs (New England Biolabs)
nd puriﬁed by neutral phenol-chloroform extraction. Linearised
NA was used as a template for in vitro transcription to produce
ull-length HCV genomic RNA (RiboMAX Express; Promega, as per
he manufacturer’s instructions). Following DNAse digestion, RNA
ranscripts were puriﬁed by acidic phenol-chloroform extraction
nd quantiﬁed by absorbance at 260 nm prior to transfection into
ammalian cells.
.2. Mammalian cell lines
An immortalised human hepatocellular carcinoma cell line,
ermed Huh-7 (Nakabayashi et al., 1982) was utilised for the
roduction and titration of all virus stocks. Huh-7 cells were main-
ained in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Sigma)
upplemented with 10% foetal bovine serum (FBS), 100 IU/mL
enicillin, 100 ug/mL streptomycin, 25 mM HEPES and 1% (v/v) non-
ssential amino acids in a humidiﬁed incubator at 37 ◦C in 5% CO2.
.3. Production of infectious HCV
For the production of virus stocks, 4.0 × 106 Huh-7 cells were
lectroporated with 5 g of viral RNA at 975 F and 260 V for 25 ms.
ells were resuspended in complete medium and seeded into T75
asks (Corning). Virus was  harvested at 48 h post-electroporation,
lariﬁed by centrifugation (10 min, 1000 × g) and stored at −80 ◦C
n 1 mL  aliquots. This allowed independent experimental replicatesal Methods 218 (2015) 59–65
to be performed from identical virus aliquots to assess data repro-
ducibility.
2.4. Virus titration
An established method of HCV titre determination has been
previously reported (Yi, 2010; Yu and Uprichard, 2010) and is
generally used in a 96 well plate format (henceforth referred to
as a standard titre plate). Brieﬂy, naïve Huh-7 cells were seeded
into 96 wellplates (8.0 × 103 cells per well, 100 L total volume)
and allowed to adhere for 16 h. Clariﬁed virus was serially diluted
two-fold into the existing media (ﬁnal volume 100 L per well).
Cells were incubated for 72 h post-infection before the detection of
viral antigens by indirect immunoﬂuorescence (Section 2.6). Virus-
positive cells were counted manually and the titre (FFU/mL) was
calculated from the wells of multiple virus dilutions.
2.5. Antiviral treatments
Huh-7 cells were electroporated with JFH-1 viral RNA as
described above and 2.5 × 104 cells were seeded into 96-well plates.
6 h post-electroporation, indicated concentrations of Daclatasvir
(SelleckChem) or Sofosbuvir (MedChem Express) were added
in duplicate with 0.25% (v/v) standard ﬁnal DMSO. 72 h post-
electroporation, viral supernatant was harvested and a 1:4 dilution
was used to infect each well of a 96 well plate of naïve Huh-7 cells
(seeded 6 h prior). 48 h post-infection, these cells were ﬁxed with
4% paraformaldehyde and viral antigens were detected by indi-
rect immunoﬂuorescence. The total number of virus-positive cells
therefore reﬂects the degree of inhibition exerted by the compound
upon the original producer cells, as measured in released infectious
units. 50% effective concentration (EC50) values were calculated
using Prism (GraphPad).
2.6. Immunoﬂuorescence
Infected cells were washed with phosphate-buffered saline
(PBS), ﬁxed with 4% paraformaldehyde for 15 min  and extensively
washed again with PBS. The ﬁxed monolayer was permeabilised
with 0.1% Triton-X100 in PBS (v/v), washed and incubated for
>2 h in primary antibody raised against a viral antigen. Anti-NS5A
(polyclonal sheep serum – Macdonald et al., 2003) and anti-core
(Moradpour et al., 1996) (C7-50, Thermo Scientiﬁc) primary anti-
bodies were used at 1:2000 dilutions (in PBS with 10% FBS),
whereas anti-E2 (Owsianka et al., 2005) (AP33, Genentech) was
used at 1:500. After further washing, cells were incubated with a
ﬂuorophore-conjugated secondary antibody (diluted 1:500 in PBS
with 10% FBS) for 2 h and ﬁnally stored in PBS prior to visualisation
and/or manual counting.
2.7. Use of the IncuCyte ZOOM
Following immunoﬂuorescence staining for viral antigens, with
either an AlexaFluor594-conjugated (“red”) or 488-conjugated
(“green”) secondary antibody, microtitre plates were imaged with
the IncuCyte ZOOMinstrument (Essen BioScience). The default soft-
ware parameters for a 96 well plate (Corning) with a 10× objective
were used for imaging. The IncuCyte software was used to calculate
mean conﬂuence from four non-overlapping bright phase images
of each well. The mean number of “red” and/or “green” positive
cells per image was calculated from four non-overlapping ﬂuo-
rescent images; this value was then extrapolated by the IncuCyte
ZOOM software to calculate the total predicted number of virus-
positive cells per well. Viral titres were obtained by multiplying
the number of virus-positive cells per wells by the reciprocal of
the corresponding dilution factor, corrected for input volume. As
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Fig. 1. Optimisation of IncuCyte ZOOM software parameters for accurate counting of NS5A-positive cells. Images from a microtitre plate were analysed eight times, using
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. Results
.1. Optimisation of software parameters
The standard virus titration protocol (described in Section 2.4)
as used to manually determine the titres of JC-1, JFH-1 and
FH-1-GND stocks. Infected cells were ﬁxed at 72 h post-infection
nd treated with a HCV NS5A-speciﬁc sheep polyclonal serum
Macdonald et al., 2003) and anti-sheep secondary antibody con-
ugated to the AlexaFluor 594 dye (Life Technologies). Plates were
anually counted by three individuals and the average titres were
alculated. Titres of 2.82 × 105 (JC-1), 3.01 × 104 (JFH-1) and 0.00
JFH-1-GND) FFU/mL were determined (Fig. 1).
This plate was then imaged with the IncuCyte ZOOM. The
umber of “red cells per well” was calculated multiple times
sing a variety of software parameter permutations (Table 1).
he optimal settings were determined to be a red calibrated unit
RCU) minimum threshold of 2.5, edge sensitivity of −30, and
2n area ﬁlter ranging from 300 to 4000 m (Fig. 1). The results
rom these parameters displayed maximum correlation with the
anually determined titres. Most importantly, the JFH-1-GND
replication-defective) “titre” was minimal (<100 red artefacts per
able 1
eﬁnitions of parameters used within the IncuCyte ZOOM software.
Parameter Function
RCU threshold A ﬁxed threshold level (in red calibrated ﬂuorescence
units) is used across the image, so all objects below
this level are classiﬁed as background and not included
in  calculations
Edge sensitivity Edge split sensitivity determines whether
closely-spaced objects are separated, according to the
weak signal points between them. A larger edge
sensitivity number (i.e., 0 compared to −30) results in
more splits, producing a higher count
Area ﬁlter This function eliminates ﬂuorescent objects that are
outside the chosen size (in m2) degree of cell-edge splits). Total “red cells per well” was calculated and extrapolated
ated from three wells across the linear range of dilutions. The combination of −30
 to those from the manual counting method, as indicated on the right axis (FFU/mL).
ml), indicating that false positives and non-speciﬁc antibody bind-
ing events would not contribute signiﬁcantly to the calculated titres
of replication-competent virus. Equally, false negatives are unlikely
to occur within these parameters: the RCU threshold of 2.5 prevents
inclusion of cells which faintly stain for viral antigens; these are
unlikely to have been infected from the initial inoculum 72 h prior
to ﬁxation, and therefore are more likely to represent new early
infection events due to viral spread or background ﬂuorescence.
The exclusion of these cells would not affect accurate determina-
tion of the initial infectious viral titre.
3.2. Linear limitations of the dilution series
Following establishment of the optimal software parameters,
we next wished to determine the linear range of dilutions across
which the IncuCyte ZOOM could produce accurate titre calcula-
tions. JC-1 virus was  used to infect naïve Huh-7 cells in a two-fold
dilution series. 72 h post-infection, cells were ﬁxed and stained for
NS5A as described above. As expected, the number of virus-positive
cells versus the dilution factor displayed a logarithmic trend
(Fig. 2A), and a linear range was  observed for dilutions between 1:21
and 1:25(Fig. 2B). For this particular virus preparation, this equates
to an average titre calculation of 1.14 × 105 IU/mL. Realistically an
accurate manual count of foci and/or virus-positive cells can only
be obtained for one or two wells in a serial dilution series before
the human error will impact upon the signiﬁcance; thus this linear
range is a signiﬁcant improvement on the previously-used assay.
3.3. Optimisation of the titration protocol
The traditional method of HCV titration involved pre-seeding
the cells 16–24 h before infection, which was  then allowed to
proceed for 48–72 h before ﬁxation (Lindenbach, 2009; Yi, 2010; Yu
and Uprichard, 2010). Although a 72 h infection period may allow
a degree of viral spread (thereby obscuring accurate measurement
of the initial infectious inoculum) this extended time period was
required to ensure sufﬁcient levels of viral protein per infected cell;
hence the strength of antibody staining was  sufﬁciently high for
visualisation of infected foci by eye.
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Fig. 2. Dilutions of HCV JC-1 from 1:21 and 1:25 are within the linear range of the
IncuCyte ZOOM. Following a two-fold titration of JC-1 virus, infected cells were
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elationship was  observed for dilutions 1:21–1:25(B).
We  therefore investigated the optimal pre-seeding and infec-
ion time conditions for use with the IncuCyte ZOOM. Identical
ell numbers were maintained from previous assays (100 L of
.0 × 103 cells/mL per well). Cells were seeded 6 h or 16 h prior
o infection, which was then allowed to proceed for 24, 48 or
2 h before monolayers were ﬁxed and stained for the NS5A viral
ntigen. Plates were imaged and analysed with the optimised
arameters described in Fig. 1. The optimal conditions, producing
ow levels of false positives in the GND controls and a conﬂuence
f approximately 87%, were the combination of pre-seeding 6 h
efore infection and ﬁxation at 48 h (Fig. 3). This represents a signif-
cant increase in the rapidity of the assay compared to the previous
rotocol.
.4. Assay ﬂexibility
For the majority of experiments we utilised an in-house sheep
olyclonal serum raised against HCV NS5A (Macdonald et al., 2003),
n combination with an anti-sheep secondary antibody labelled
ith the AlexaFluor 594 dye (Life Technologies). However it is
mportant that this assay may  be adapted to utilise a range of
ommercially available primary and secondary antibodies. A virus
itration assay was performed according to the optimised protocol
cells seeded 6 h prior to infection, and ﬁxed 48 h post-infection).
ixed infected cells were then stained with commercially-available
2-speciﬁc (Owsianka et al., 2005) (AP33, Genentech) or core-
peciﬁc mouse monoclonal antibodies (Moradpour et al., 1996)
C7-50, Thermo Scientiﬁc) (Fig. 4). Both of these monoclonal anti-
odies recognise linear epitopes that are conserved across HCVal Methods 218 (2015) 59–65
genotypes and as such would be applicable to other, non-JFH-
1-based virus titration assays. Anti-mouse secondary antibodies
labelled with either the 488 (for E2 staining) or 594 dye (for
core staining) were used. It must be noted that the 488-labelled
secondary antibody displayed higher background staining and
therefore the minimal green calibrated unit (GCU) threshold was
increased to 4.5. Plates were imaged and analysed according to
the optimised software parameters. Similar titres were obtained
for both JFH-1 and JC-1 for all antibodies tested, although higher
background staining of the GND control wells was observed for
the E2-stained samples (Fig. 4). These results demonstrate that this
assay is amenable to a range of primary and secondary antibodies
and is therefore readily accessible to other laboratories.
3.5. Validation of antiviral compound screening
The increased-throughput measure of IU/mL for this assay may
be particularly useful in the study of antivirals that target mul-
tiple stages of the virus lifecycle (McGivern et al., 2014). Thus,
an adapted protocol was used to calculate EC50 values for the
direct acting antivirals Daclatasvir and Sofosbuvir, both of which
are in clinical use for HCV therapy. Cells electroporated with JFH-
1 RNA were incubated with a range of inhibitor concentrations,
before naïve cells were infected using previously optimised dilu-
tions within the accurate linear range (in this case, 1:22 as displayed
in Fig. 3). Infected cells were stained for NS5A, imaged and ana-
lysed as described. The extrapolated IU/mL was then plotted to
calculate the EC50 of each compound (Fig. 5). The values reported
(95.5 ± 27.9 nM for Sofosbuvir and 6.2 ± 3.9 pM for Daclatasvir) are
within the published range for each antiviral compound, validating
this approach for the screening of novel compounds in the future.
4. Discussion
In this paper, we  have described the optimisation of a novel
approach for analysing HCV infectious titres. The previously pub-
lished protocols involve a 4-day assay followed by lengthy manual
counting of infected cells; in contrast, our method requires only
3 days of cell incubation followed by fully automated data analy-
sis. This represents a signiﬁcant increase in processivity, as well as
improved accuracy, precision and reproducibility. The linear range
of detection that this method exhibits also means that dilution to an
endpoint is not essential, in contrast to both the focus-forming unit
and TCID50 methods. Therefore a reduced number of viral dilutions
are required for each sample, signiﬁcantly reducing the reagent cost
per assay.
Alternatives to HCV titrations have been investigated previously
but all possess signiﬁcant caveats; for example, antigen-capture
based techniques, such as core protein ELISAs, are high-throughput
but neither differentiate between defective particles and infectious
virions, nor antigen released from dead cells. Thus, such mea-
surements are poor surrogates for infectious titre assays. Other
assays rely upon the expression of reporter genes inserted into the
viral genome; for example, luciferase or green ﬂuorescent protein.
However the quantiﬁcation of a reporter gene relies upon assump-
tion of a linear relationship between reporter expression levels and
infectious units; a controversial assumption which would require
validation for each novel clone produced. Equally concerning is the
fact that insertion of a reporter gene tends to decrease viral ﬁtness
(Vieyres and Pietschmann, 2013). As research is focussed increas-
ingly upon the development of novel, non-JFH-1-based infectious
clones, which are more relevant to clinical isolates but tend to
display low infectious titres, insertion of a reporter is unlikely to
represent a feasible option. To circumvent this, reporter-based cell
lines have been described which facilitate the study of native virus
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Fig. 3. Optimisation of pre-seeding and infection time periods. Cells were seeded either 6 or 16 h prior to infection, which was  then allowed to proceed for 24, 48 or 72 h
before  ﬁxation. The optimal conﬂuency was obtained when cells were seeded at −6 h and ﬁxed at 48 h post-infection (A); this correlated to the lowest background count of
red  cells per well in the GND controls (B) and is therefore the optimal time frame. Data represents the mean + SEM of titres calculated from three independently infected titre
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Iro et al., 2009; Jones et al., 2010). These offer an attractive method
or the quantiﬁcation of HCV titres that is genotype independent,
ut require the establishment of an appropriate cell line expressing
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esidues of the mitochondrial antiviral signalling protein (MAVS).
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, 48 h infection duration panel (central left).
and a cleavage site for NS3/4A. Upon infection, NS3/4A cleaves
this reporter and the ﬂuorescent protein is released from the
mitochondria and translocates to the cell nucleus. The image pro-
cessing required to distinguish between uninfected and infected
cells using this approach is thus substantially more complex
than that described here which simply enumerates positive cells
identiﬁed by immunostaining. Our method may  potentially be
applicable to multiple infectious HCV isolates, given the successful
NS5A
JC-1
JFH-1
JFH-1-GND
yte ZOOM-adapted titration protocol. Following infection and ﬁxation, cells were
ised parameters. Similar titre values for JFH-1 and JC-1 isolates were obtained for
e independently infected titre plates.
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Fig. 5. The IncuCyte ZOOM titration assay predicts accurate EC50 values for known
antivirals and is therefore applicable for the identiﬁcation of novel compounds. Elec-
troporated cells were treated with a range of concentrations of anti-HCV antiviral
compounds, Sofosbuvir (A) or Daclatasvir (B). Virus was harvested at 72 h and a 1:22
dilution was  used to infect naïve Huh-7 cells. 48 h post-infection, cells were ﬁxed
and stained for NS5A. Calculated titres were plotted and used to predict EC50 values
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se of various primary antibodies targeting conserved epitopes.
o the best of our knowledge, this is the ﬁrst automated, high-
hroughput method of accurately analysing viral infectious titres,
hich does not rely upon expression of a reporter gene.
This method has applications for multiple areas of HCV research,
s most require accurate measurements of viral release and infec-
ivity. We  predict the main use to be in the identiﬁcation and
alidation of novel antiviral compounds. The reported EC50 for
ofosbuvir is 558 nM for a genotype 2a/2a chimaeric JFH-1-based
nfectious virus (Ramirez et al., 2014); in comparison, Daclatasvir
xerts an EC50 of 28 pM (Gao et al., 2010). Therefore our reported
alculations are within the expected range for infectious virus
or both compounds (Fig. 5); this validates the use of our assay
or the accurate calculation of EC50 values. Equally, the measure-
ent of neutralising antibody titres would beneﬁt signiﬁcantly
rom an adaptation of our protocol. A reduction in foci (caused
y infectious virus following incubation with patient sera) is
lready commonly used as a method of assessing neutralising
otential (Fournier et al., 2007); the application of our optimised
rotocol would signiﬁcantly enhance the throughput of these
tudies.
In conclusion, we have developed and optimised a novel method
f measuring and analysing HCV infectious titres, which requires
he use of the IncuCyte ZOOM instrument and associated software.
his assay will prove useful for all basic research involving novel
nfectious HCV isolates and the identiﬁcation of novel antivirals
argeting multiple stages of the viral life cycle.al Methods 218 (2015) 59–65
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